Search all CCR Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0013Investigator Scott M. Norberg, D.O. -
A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-048Investigator William L. Dahut, M.D. -
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in patients with advanced cancer
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0007Investigator Houssein Abdul Sater, M.D. -
Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)
Open - RecruitingNCI Protocol ID NCI-20-C-0167Investigator Steven Z. Pavletic, M.D., M.S. -
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Selection and Disease Progression in Patients Undergoing Active Surveillance for Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0164Investigator Peter A. Pinto, M.D. -
Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0006Investigator Jonathan M. Hernandez, M.D.Share this trial: Referral ContactsContact Name Phone Number -
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0169Investigator Milos Miljković, M.D., M.Sc. -
Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients with Unresectable Pulmonary Metastases from Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0004Investigator David S. Schrump, M.D., M.B.A. -
A Phase I/II Study of Bintrafusp alfa (M7824) and M9241 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0001Investigator Ravi A. Madan, M.D. -
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-067Investigator Haneen Shalabi, D.O.Share this trial: Referral ContactsContact Name Phone Number NCI Pediatric Leukemia Lymphoma BMT Team (240)760-6970 -
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0152Investigator Tim F. Greten, M.D. -
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies#xD;
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0162Investigator Mark Roschewski, M.D. -
Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Open - RecruitingNCI Protocol ID NCI-20-C-0161Investigator Andrew M. Blakely, M.D.Share this trial: Referral ContactsContact Name Phone Number Cathleen Hannah 240-409-8860 NIH Foregut team 240-858-3610 -
A phase 1/2, open label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors
Open - RecruitingNCI Protocol ID NCI-20-C-0098Investigator Marijo Bilusic, M.D., Ph.D. -
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-ß “Trap”/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT).
Open - RecruitingNCI Protocol ID NCI-20-C-0155Investigator James L. Gulley, M.D., Ph.D. -
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors.
Open - RecruitingNCI Protocol ID NCI-20-C-0149Investigator Anish Thomas, MBBS, M.D. -
Phase II Randomized Trial of Bethesda Protocol compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0150Investigator Jeremy L. Davis, M.D. -
Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers
Open - RecruitingNCI Protocol ID NCI-20-C-0138Investigator Julius Strauss, M.D. -
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naïve and Refractory Subjects with Urothelial Carcinoma
Open - RecruitingNCI Protocol ID NCI-20-C-0142Investigator Andrea B. Apolo, M.D. -
A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-20-C-0069Investigator Mark R. Gilbert, M.D.